Tetiana V Serebrovska1, Alla G Portnychenko2,3, Vladimir I Portnichenko2,3, Lei Xi4,5, Egor Egorov6, Ivanna Antoniuk-Shcheglova7, Svitlana Naskalova7, Valeriy B Shatylo7. 1. Bogomoletz Institute of Physiology, Kiev, 01024, Ukraine. sereb@biph.kiev.ua. 2. Bogomoletz Institute of Physiology, Kiev, 01024, Ukraine. 3. ICAMER, National Academy of Sciences of Ukraine, Kiev, 03680, Ukraine. 4. Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, 1101 East Marshall Street, Room 7-020C, Richmond, VA, 23298, USA. lxi@vcu.edu. 5. School of Sports Medicine and Health, Chengdu Sport University, Chengdu, 610041, China. lxi@vcu.edu. 6. CELLGYM Technologies GmbH, 10623, Berlin, Germany. 7. D.F. Chebotarev State Institute of Gerontology, Kiev, 04114, Ukraine.
Abstract
PURPOSE: Intermittent hypoxia training/treatment (IHT) is an emerging therapeutic approach to alleviate chronic diseases, such as diabetes. The present study investigated the effects of IHT on blood leucocyte pyruvate dehydrogenase kinase 1 (PDK-1) mRNA expression and its relationship with the changes in blood insulin level. METHODS: Seven adult healthy volunteers and 11 prediabetic patients participated in this study. A 3-week course of IHT consisted of a 40-min session of 4 cycles of 5-min 12% O2 and 5-min room air breathing per day, 3 sessions per week for 3 weeks (i.e., total 9 sessions of IHT). Plasma insulin levels and leukocyte PDK-1 mRNA expression were determined at various time points either under fasting condition or following oral glucose tolerance test (OGTT). Correlation between the IHT-induced changes in PDK-1 mRNA and insulin or glucose levels in the same serological samples was analyzed. RESULTS: At pre-IHT baseline, PDK-1 mRNA expression was two times higher in prediabetes than control subjects. IHT resulted in significant augmentation in PDK-1 mRNA expression (> twofold) in prediabetes at the end of 3-week IHT and remained elevated 1 month after IHT, which was correlated with a significantly reduced insulin release and lower blood glucose after glucose loading with OGTT. CONCLUSION: IHT can trigger beneficial effects in normalizing blood insulin levels in prediabetic patients under oral glucose load, which were closely correlated with an enhanced mRNA expression of PDK-1 in leukocytes. Further clinical trials are warranted to validate the utility of IHT as a non-invasive complementary therapy against diabetes-associated pathologies.
PURPOSE: Intermittent hypoxia training/treatment (IHT) is an emerging therapeutic approach to alleviate chronic diseases, such as diabetes. The present study investigated the effects of IHT on blood leucocyte pyruvate dehydrogenase kinase 1 (PDK-1) mRNA expression and its relationship with the changes in blood insulin level. METHODS: Seven adult healthy volunteers and 11 prediabeticpatients participated in this study. A 3-week course of IHT consisted of a 40-min session of 4 cycles of 5-min 12% O2 and 5-min room air breathing per day, 3 sessions per week for 3 weeks (i.e., total 9 sessions of IHT). Plasma insulin levels and leukocyte PDK-1 mRNA expression were determined at various time points either under fasting condition or following oral glucose tolerance test (OGTT). Correlation between the IHT-induced changes in PDK-1 mRNA and insulin or glucose levels in the same serological samples was analyzed. RESULTS: At pre-IHT baseline, PDK-1 mRNA expression was two times higher in prediabetes than control subjects. IHT resulted in significant augmentation in PDK-1 mRNA expression (> twofold) in prediabetes at the end of 3-week IHT and remained elevated 1 month after IHT, which was correlated with a significantly reduced insulin release and lower blood glucose after glucose loading with OGTT. CONCLUSION: IHT can trigger beneficial effects in normalizing blood insulin levels in prediabeticpatients under oral glucose load, which were closely correlated with an enhanced mRNA expression of PDK-1 in leukocytes. Further clinical trials are warranted to validate the utility of IHT as a non-invasive complementary therapy against diabetes-associated pathologies.
Authors: S J Peters; R A Harris; P Wu; T L Pehleman; G J Heigenhauser; L L Spriet Journal: Am J Physiol Endocrinol Metab Date: 2001-12 Impact factor: 4.310
Authors: Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: S Sakata; S Shimizu; T Kishi; K Hirai; I Mori; Y Ohno; M Ueda; M Takaki; H Kohzuki; S Okamoto; I Shimamoto; S Yanagi; K Ogoshi; J B Sherchand Journal: Jpn J Physiol Date: 2000-04
Authors: Zoya O Serebrovska; Lei Xi; Lesya V Tumanovska; Angela M Shysh; Sergii V Goncharov; Michael Khetsuriani; Taisia O Kozak; Denis A Pashevin; Victor E Dosenko; Sergii V Virko; Viktor A Kholin; Oksana N Grib; Natalie A Utko; Egor Egorov; Anna O Polischuk; Tetiana V Serebrovska Journal: Life (Basel) Date: 2022-03-16